These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7009616)

  • 1. Monkey neurovirulence of live, attenuated (Sabin) type I and type II poliovirus vaccines.
    Marsden SA; Boulger LR; Magrath DI; Reeve P; Schild GC; Taffs LF
    J Biol Stand; 1980; 8(4):303-9. PubMed ID: 7009616
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of a mathematical model for neurovirulence assay of attenuated poliovirus.
    Arya SC
    J Biol Stand; 1977; 5(4):283-7. PubMed ID: 200629
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative monkey neurovirulence of Sabin type III poliovirus vaccines.
    Boulger LR; Marsden SA; Magrath DI; Taffs LF; Schild GC
    J Biol Stand; 1979 Apr; 7(2):97-111. PubMed ID: 225329
    [No Abstract]   [Full Text] [Related]  

  • 4. The behaviour of Sabin attenuated poliovirus strains in the central nervous system of rhesus monkeys.
    Arya SC
    J Biol Stand; 1977; 5(4):275-81. PubMed ID: 200628
    [No Abstract]   [Full Text] [Related]  

  • 5. Live attenuated oral poliovirus vaccine.
    Melnick JL
    Rev Infect Dis; 1984; 6 Suppl 2():S323-7. PubMed ID: 6330836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
    Kohara M; Abe S; Yoshioka I; Nomoto A
    Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.
    Chumakov KM; Powers LB; Noonan KE; Roninson IB; Levenbook IS
    Proc Natl Acad Sci U S A; 1991 Jan; 88(1):199-203. PubMed ID: 1846038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible influence of measles virus infection of cynomolgus monkeys on the outcome of the neurovirulence test for oral poliovirus vaccine.
    Contreras G; Furesz J
    Biologicals; 1992 Mar; 20(1):27-33. PubMed ID: 1319180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
    Furesz J; Contreras G
    Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live attenuated oral poliovirus vaccine: problem areas in production.
    Beale AJ
    Rev Infect Dis; 1984; 6 Suppl 2():S334. PubMed ID: 6429813
    [No Abstract]   [Full Text] [Related]  

  • 12. WHO recommendation on potential use of new poliomyelitis vaccines.
    Ghendon Y
    Dev Biol Stand; 1993; 78():133-7; discussion 138-9. PubMed ID: 8388823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
    Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
    Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetical analysis on the stability of poliovirus type 3 Leon 12a1b.
    Nakano M; Matsukura T; Yoshii K; Komatsu T; Mukoyama A; Uchida N; Kodama H; Tagaya I
    J Biol Stand; 1979 Jul; 7(3):157-68. PubMed ID: 227906
    [No Abstract]   [Full Text] [Related]  

  • 15. Standardization of reference preparations-factors influencing assay of attenuated polioviruses.
    Arya SC
    Indian J Med Res; 1975 May; 63(5):625-30. PubMed ID: 1213762
    [No Abstract]   [Full Text] [Related]  

  • 16. On the role of the World Health Organization in the development of Sabin vaccines.
    Magrath D; Reeve P
    Biologicals; 1993 Dec; 21(4):345-8. PubMed ID: 8024749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience in Canada with the new revised monkey neurovirulence test for oral poliovirus vaccine.
    Contreras G; Furesz J; Karpinski K; Grinwich K; Gardell C
    J Biol Stand; 1988 Jul; 16(3):195-205. PubMed ID: 2844825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardization of safety and potency tests of vaccines against poliomyelitis.
    Elisberg BL
    Rev Infect Dis; 1984; 6 Suppl 2():S519-22. PubMed ID: 6330850
    [No Abstract]   [Full Text] [Related]  

  • 19. Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control.
    Rezapkin GV; Norwood LP; Taffs RE; Dragunsky EM; Levenbook IS; Chumakov KM
    Virology; 1995 Aug; 211(2):377-84. PubMed ID: 7645242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On stability of oral poliovirus vaccines.
    Mauler R; Gruschkau H
    Dev Biol Stand; 1978; 41():267-70. PubMed ID: 38157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.